Foreign Inventors: Hire US Patent Pros or Bust
Published Date: 12/29/2025
Proposed Rule
Summary
Starting soon, foreign inventors and patent owners will need to work with a registered U.S. patent expert to file or manage their patents. This change helps the USPTO keep things fair, fight fraud, and match rules used in other countries. If you’re affected, get ready to team up with a licensed patent pro by early 2026—no extra fees mentioned yet, but don’t miss the January 28 comment deadline!
Analyzed Economic Effects
5 provisions identified: 0 benefits, 5 costs, 0 mixed.
Foreign Applicants Must Use U.S. Patent Counsel
If any party named as an applicant or patent owner has a domicile outside the United States or its territories, that foreign applicant/inventor or patent owner must be represented by a registered U.S. patent practitioner (a registered patent attorney or agent, or someone given limited recognition). This requirement applies to all application types (utility, plant, design, etc.).
USPTO Will Reject Unsigned Pro Se Papers
When representation by a registered patent practitioner is required, the USPTO will not enter amendments, replies, application data sheets (ADS), information disclosure statements, or petitions into the application or patent record unless those papers are signed by a registered patent practitioner. Papers that must be signed by a specific party (for example, the inventor's oath or declaration under 37 CFR 1.63) are excluded.
Estimated Small-Entity Legal Costs and How Many Are Affected
The USPTO identified 1,217 foreign pro se applications in FY2022, of which 1,102 were filed by small entities. The Office estimates total legal costs for those 1,102 foreign pro se small-entity non-provisional applications would range from about $4.34 million to $5.40 million if minimal U.S. practitioner services are needed, and from about $13.12 million to $19.40 million if full U.S. practitioner prosecution services are required.
Juristic Entity Patent Owners Must Be Represented
The proposed rule explicitly requires a patent owner that is a juristic entity (a legal entity) whose domicile is outside the U.S. or its territories to be represented by a registered patent practitioner, including in post-grant proceedings. This expands a prior requirement that applied to juristic entities as applicants to also cover patent owners.
Who Counts as 'Foreign' for This Rule
The rule applies when at least one party identified as the applicant or patent owner has a "domicile" not located within the U.S. or its territories. The proposed 37 CFR 1.9(p) defines domicile as the permanent legal place of residence for a natural person or the principal place of business for a juristic entity, and the application data sheet (ADS) normally controls domicile determination.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16744, Request for Comments on Community Outreach Office Locations in the Southwest States
The USPTO wants your ideas on where to open new community outreach offices in the Southwest states like Arizona and Texas. These offices will help inventors, small businesses, and students get better support with patents. Share your thoughts by September 16, 2026, so the USPTO can pick the best spots and keep innovation booming without extra costs to you!
2026-16315, Administrative Updates to the General Requirements Bulletin for Admission to the Examination for Registration To Practice in Patent Cases Before the United States Patent and Trademark Office
Starting August 11, 2026, the USPTO is upgrading Biomedical Science degrees from Category B to Category A for patent bar eligibility. This means more people with this degree can now take the patent exam and become patent practitioners. No extra fees or delays—just a smoother path for those with the right science background to join the patent world!
2026-14941, Grant of Interim Extension of the Term of U.S. Patent No. 8,461,196; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means they keep exclusive rights to the drug until July 25, 2027, giving them more time to sell it without competition. This extension helps the company protect their investment while the drug gets final approval.
2026-14939, Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means their patent, which was set to expire on July 25, 2026, now lasts until July 25, 2027. This extension helps Otsuka keep exclusive rights to their drug a bit longer while waiting for final FDA approval.
2026-14793, Requirement To Identify All Real Parties in Interest to a Third Party Request for an Ex Parte Reexamination
The USPTO wants anyone asking for a third-party ex parte reexamination to clearly say who’s really behind the request. This helps stop sneaky tricks and keeps the process honest. If you’re involved, get ready to share this info confidentially by August 21, 2026, or risk delays or issues.
2026-14388, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Admission to Practice and Roster of Registered Patent Attorneys and Agents Admitted to Practice Before the United States Patent and Trademark Office
The USPTO is asking for public feedback on its paperwork rules for patent attorneys and agents who want to practice before the office. This helps keep the process smooth and fair without making people fill out too many forms. If you have thoughts, send them in by August 17, 2026—no fees or big changes are happening right now, just a review.
Previous / Next Documents
Previous: 2025-23896, Health Data, Technology, and Interoperability: ASTP/ONC Deregulatory Actions To Unleash Prosperity
This new rule aims to cut red tape around health data technology, making it easier for developers and healthcare providers to innovate and share info. It fixes problems with confusing rules about blocking information and offers more flexibility, saving time and money. Comments on the proposal are open until February 27, 2026, so stakeholders can weigh in before changes take effect.
Next: 2025-23963, Implementation of the Administrative False Claims Act
NASA is updating its rules to crack down on people or companies who knowingly lie or cheat NASA for money. This new process lets NASA quickly handle smaller fraud cases without waiting for big court battles, protecting taxpayer dollars better. If you want to share your thoughts, get your comments in by February 13, 2026!